Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Citi
Merck
UBS
Accenture
Moodys
Cerilliant
Farmers Insurance
Boehringer Ingelheim

Generated: August 16, 2018

DrugPatentWatch Database Preview

Zydus Pharms Usa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ZYDUS PHARMS USA INC, and when can generic versions of ZYDUS PHARMS USA INC drugs launch?

ZYDUS PHARMS USA INC has one hundred and forty-eight approved drugs.

There is one US patent protecting ZYDUS PHARMS USA INC drugs. There are eight tentative approvals on ZYDUS PHARMS USA INC drugs.

There are two patent family members on ZYDUS PHARMS USA INC drugs in two countries and one hundred and eighty-nine supplementary protection certificates in twelve countries.

Summary for Zydus Pharms Usa Inc
International Patents:2
US Patents:1
Tradenames:126
Ingredients:125
NDAs:148

Drugs and US Patents for Zydus Pharms Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc DIVALPROEX SODIUM divalproex sodium TABLET, DELAYED RELEASE;ORAL 077100-001 Mar 5, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 203894-004 Mar 23, 2018 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc PRAMIPEXOLE DIHYDROCHLORIDE pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 202891-005 Dec 12, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc TELMISARTAN telmisartan TABLET;ORAL 203325-002 Aug 26, 2014 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc GLYBURIDE glyburide TABLET;ORAL 206749-002 May 10, 2016 AB1 RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc ACYCLOVIR acyclovir CAPSULE;ORAL 204313-001 Mar 25, 2016 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc ROPINIROLE HYDROCHLORIDE ropinirole hydrochloride TABLET;ORAL 090411-003 Jun 1, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ZYDUS PHARMS USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Non-Orange Book US Patents for Zydus Pharms Usa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,139,527 Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Zydus Pharms Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/018 Ireland ➤ Sign Up PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
C/GB05/003 United Kingdom ➤ Sign Up PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
C0030 France ➤ Sign Up PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
02C/035 Belgium ➤ Sign Up PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
C0001 Belgium ➤ Sign Up PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
C/GB98/047 United Kingdom ➤ Sign Up PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
/2001 Austria ➤ Sign Up PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKinsey
Julphar
Cipla
Argus Health
Moodys
Harvard Business School
QuintilesIMS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.